| Autor: |
Hazar V; Department of Pediatric Hematology&Oncology and BMT Unit, Medical Park Göztepe Hospital, Istanbul., Karasu GT; Department of Pediatric Hematology&Oncology and BMT Unit, Medical Park Göztepe Hospital, Istanbul., Uygun V; Department of Pediatric Hematology&Oncology and BMT Unit, Medical Park Antalya Hospital, Antalya., Öztürk G; Department of Pediatric Hematology&Oncology and BMT Unit, Acibadem University Faculty of Medicine, Acibadem Atakent Hospital, Istanbul., Kiliç SÇ; Department of Pediatric Hematology&Oncology and BMT Unit, Medical Park Göztepe Hospital, Istanbul., Küpesiz A; Department of Pediatric Hematology&Oncology and BMT Unit, Akdeniz University Faculty of Medicine, Antalya., Daloglu H; Department of Pediatric Hematology&Oncology and BMT Unit, Medical Park Antalya Hospital, Antalya., Aksoylar S; Department of Pediatric Hematology&Oncology and BMT Unit, Ege University Faculty of Medicine, Izmir., Atay D; Department of Pediatric Hematology&Oncology and BMT Unit, Acibadem University Faculty of Medicine, Acibadem Atakent Hospital, Istanbul., Ince EÜ; Department of Pediatric Hematology&Oncology and BMT Unit, Ankara University Faculty of Medicine, Ankara., Karakükçü M; Department of Pediatric Hematology&Oncology and BMT Unit, Erciyes University Faculty of Medicine, Kayseri., Özbek N; Department of Pediatric Hematology&Oncology and BMT Unit, Ankara Child Health and Diseases Hematology Oncology Training and Research Hospital, Ankara., Tayfun F; Department of Pediatric Hematology&Oncology and BMT Unit, Akdeniz University Faculty of Medicine, Antalya., Kansoy S; Department of Pediatric Hematology&Oncology and BMT Unit, Ege University Faculty of Medicine, Izmir., Özyürek E; Department of Pediatric Hematology&Oncology and BMT Unit, Medical Park Samsun Hospital, Samsun., Akçay A; Department of Pediatric Hematology&Oncology and BMT Unit, Acibadem University Faculty of Medicine, Acibadem Atakent Hospital, Istanbul., Gürsel O; Department of Pediatric Hematology&Oncology and BMT Unit, Gülhane Military Medical Academy, Ankara., Haskologlu S; Department of Pediatric Hematology&Oncology and BMT Unit, Ankara University Faculty of Medicine, Ankara., Kaya Z; Department of Pediatric Hematology&Oncology and BMT Unit, Gazi University Faculty of Medicine, Ankara., Yilmaz S; Department of Pediatric Hematology&Oncology and BMT Unit, Dokuz Eylül University Faculty of Medicine, Izmir., Tanyeli A; Department of Pediatric Hematology&Oncology and BMT Unit, Çukurova University Faculty of Medicine, Adana., Yesilipek A; Department of Pediatric Hematology&Oncology and BMT Unit, Medical Park Antalya Hospital, Antalya.; The Chief of the Turkish Pediatric BMT Study Group. |
| Abstrakt: |
Invasive fungal infections (IFIs) are a major cause of infection-related morbidity and mortality in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Data from pediatric settings are scarce. To determine the incidence, risk factors and outcomes of IFIs in a 180-day period post-transplantation, 408 pediatric patients who underwent allogeneic HSCT were retrospectively analyzed. The study included only proven and probable IFIs. The cumulative incidences of IFI were 2.7%, 5.0%, and 6.5% at 30, 100, and 180 days post-transplantation, respectively. According to the multivariate analysis, the factors associated with increased IFI risk in the 180-day period post-HSCT were previous HSCT history (hazard ratio [HR], 4.57; 95% confidence interval [CI] 1.42-14.71; P = .011), use of anti-thymocyte globulin (ATG) (HR, 2.94; 95% CI 1.27-6.80; P = .012), grade III-IV acute graft-versus-host-disease (GVHD) (HR, 2.91; 95% CI 1.24-6.80; P = .014) and late or no lymphocyte engraftment (HR, 2.71; 95% CI 1.30-5.62; P = .007). CMV reactivation was marginally associated with an increased risk of IFI development (HR, 1.91; 95% CI 0.97-3.74; P = .063). IFI-related mortality was 1.5%, and case fatality rate was 27.0%.The close monitoring of IFIs in pediatric patients with severe acute GVHD who receive ATG during conditioning is critical to reduce morbidity and mortality after allogeneic HSCT, particularly among those with prior HSCT and no or late lymphocyte engraftment. |
